S elvin et al. (1) add their contribution to the existing extensive evidence of ethnic and racial differences in hemoglobin glycation that compares, in part, non-Hispanic whites with African Americans in the Diabetes Prevention Program (2), Europid with Inuit in Denmark (3), and Africans from Rodrigues with South Asians, Chinese, and Africans from the main island of Mauritius (4) . HbA 1c use as a diagnostic test for diabetes, then, would be expected to lead to more false-positive results for the latter groups in each of these comparisons (5).
Selvin et al. have examined the effect of race on the utility of HbA 1c to predict renal and cardiovascular complications during 18 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) study and purport to show that a similar interpretation of HbA 1c in blacks and whites can be made for the diagnosis and treatment of diabetes. We suspect that that the data from their study actually indicates the opposite. No one could be surprised that, as they show, increasing HbA 1c is associated with increasing complication risk in both blacks and whites. The nub of the issue is whether blacks have a different risk of complications than whites at the same HbA 1c . This is difficult to ascertain among black subjects with HbA 1c $ 6.5% (48 mmol/mol), whose HbA 1c was 7.4 6 1.5% (see Table  1 in Selvin et al. [1] ). In the more clearly defined 5.7-6.4% (39-47 mmol/mol) range, however, Table 2 Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http:// creativecommons.org/licenses/by-nc-nd/3.0/ for details.
